EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Altered Estrogen Receptor Signaling Pathway in BRCA2 ‐Deficient Estrogen Receptor‐Positive/ HER2 ‐Negative Breast Cancer

Kaori Kawasaki iD, Misato Masuyama iD, Masafumi Shimoda iD, Ikumi Seto iD, Chieko Mishima iD, Yoshiaki Sota iD, Kaori Abe iD, Nanae Masunaga iD, Masami Tsukabe iD, Tetsuhiro Yoshinami iD, Tomohiro Miyake iD, Tomonori Tanei iD und 1 weitere

Cancer Reports · 2026

DOI: 10.1002/cnr2.70558 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Reports, 2026. Verfasst von Kaori Kawasaki und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan. Hauptthemen laut MEDLINE: Breast Neoplasms, BRCA2 Protein, Receptors, Estrogen. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hereditary breast cancer accounts for approximately 10% of all breast cancer cases, with germline BRCA2 pathogenic variants (PVs) being the most prevalent genetic alteration. BRCA2 PVs predominantly lead to estrogen receptor (ER)‐positive/HER2‐negative breast cancers, which exhibit more aggressive phenotypes compared to sporadic cases. However, the specific effect of BRCA2 deficiency on ER signaling remains poorly understood.

Aims

This study aimed to elucidate the relationship between BRCA2 deficiency and ER signaling using integrated clinical and in vitro analyses. Methods and Results Immunohistochemical analyses were performed on ER‐positive/HER2‐negative breast tumors from BRCA2 PV carriers ( n = 8) and BRCA2 wild‐type patients ( n = 59). Furthermore, two BRCA2 ‐deficient ER‐positive/HER2‐negative MCF7 cell lines were generated using CRISPR‐Cas9 with two distinct guide RNAs targeting BRCA2 , followed by Western blotting and functional assays. Immunohistochemical analyses demonstrated significantly lower levels of phosphorylated (p)‐ER Ser167, p‐AKT Ser473, and RB1 in BRCA2 PV carriers compared to patients with BRCA2 wild‐type ( p = 0.002, 0.018, and 0.037, respectively). Western blotting confirmed reduced p‐ER Ser167, p‐AKT Ser473, and RB1 levels in BRCA2 ‐deficient cells relative to parental MCF7 cells. Decreased ER and AKT phosphorylation was not associated with consistent changes in the expression levels of downstream estrogen‐responsive genes or proteins. Functional assays revealed that BRCA2 deficiency significantly increased sensitivity to the poly (ADP‐ribose) polymerase inhibitor olaparib, whereas tamoxifen sensitivity remained unchanged.

Conclusion

This study presents the first detailed characterization of ER signaling alterations in ER‐positive/HER2‐negative breast cancers with germline BRCA2 PVs, offering insights for the development of targeted therapeutic strategies for this patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsBRCA2 ProteinReceptors, EstrogenHumansFemaleErb-b2 Receptor Tyrosine KinasesSignal TransductionMCF-7 CellsPiperazinesMiddle AgedPhthalazinesGerm-Line MutationAdultPhosphorylationTamoxifenPoly(ADP-ribose) Polymerase InhibitorsAged

Stichwörter der Autor:innen

BRCA mutationsbreast cancerestrogen receptor alphaphosphorylationsignal transductiontranslational research

Substanzen

Erb-b2 Receptor Tyrosine KinasesBRCA2 ProteinERBB2 protein, humanBRCA2 protein, humanPiperazinesReceptors, EstrogenPhthalazinesolaparibTamoxifenPoly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.

ORCID-Profile: Kaori Kawasaki, Misato Masuyama, Masafumi Shimoda, Ikumi Seto, Chieko Mishima, Yoshiaki Sota, Kaori Abe, Nanae Masunaga, Masami Tsukabe, Tetsuhiro Yoshinami, Tomohiro Miyake, Tomonori Tanei, Kenzo Shimazu

Förderung

  • Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science

Zitieren

APA

Kawasaki, K., Masuyama, M., Shimoda, M., Seto, I., Mishima, C., Sota, Y., Abe, K., Masunaga, N., Tsukabe, M., Yoshinami, T., Miyake, T., Tanei, T., & Shimazu, K. (2026). Altered Estrogen Receptor Signaling Pathway in BRCA2 ‐Deficient Estrogen Receptor‐Positive/ HER2 ‐Negative Breast Cancer. Cancer Reports. https://doi.org/10.1002/cnr2.70558

Vancouver

Kawasaki K, Masuyama M, Shimoda M, Seto I, Mishima C, Sota Y, et al. Altered Estrogen Receptor Signaling Pathway in BRCA2 ‐Deficient Estrogen Receptor‐Positive/ HER2 ‐Negative Breast Cancer. Cancer Reports. 2026. doi:10.1002/cnr2.70558

BibTeX
@article{Kawasaki2026,
  author = {Kawasaki, Kaori and Masuyama, Misato and Shimoda, Masafumi and Seto, Ikumi and Mishima, Chieko and Sota, Yoshiaki and Abe, Kaori and Masunaga, Nanae and Tsukabe, Masami and Yoshinami, Tetsuhiro and Miyake, Tomohiro and Tanei, Tomonori and Shimazu, Kenzo},
  title = {Altered Estrogen Receptor Signaling Pathway in BRCA2 ‐Deficient Estrogen Receptor‐Positive/ HER2 ‐Negative Breast Cancer},
  journal = {Cancer Reports},
  year = {2026},
  doi = {10.1002/cnr2.70558}
}
Kostenlos starten →